ArticleCell death and differentiation2026
OR2T6 modulates autophagy through the PPP3CA-mediated pathways to suppress gastric cancer.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The role of autophagy in gastric cancer (GC) progression remains elusive, warranting further investigation into its mechanisms and therapeutic implications. In this study, we demonstrate that olfactory receptor family 2 subfamily T member 6 (OR2T6) is downregulated and correlates with poorer prognosis in GC tissues. Functionally, OR2T6 induces autophagy initiation while blocking autophagic flux by compromising lysosomal function and inhibits cell proliferation both in vitro and in vivo. Mechanistically, co-immunoprecipitation (Co-IP) and mass spectrometry (MS) analyses reveal that OR2T6 specifically binds to PPP3CA. OR2T6 facilitates the protein stability and enzyme activity of PPP3CA through the ubiquitin-proteasome system and the promotion of calcium ion influx via the Gs/cAMP/PKA channel signaling axis. Our further research demonstrates that OR2T6 binds to PPP3CA, which suppresses the AKT/mTOR signaling pathway, thereby inhibiting tumor proliferation and promoting autophagy initiation. Interestingly, it facilitates the nuclear translocation of TFEB, a key regulator of lysosomal biogenesis, which leads to the transcriptional inactivation of lysosomal target genes (LAMP1, MCOLN1, ATP6V1H, CTSB, and CTSD), impairing lysosomal function and blocking autophagic flux. Collectively, we report that OR2T6 binds to and promotes PPP3CA, which subsequently initiates autophagy, inhibits proliferation by suppressing the AKT/mTOR pathway, and then blocks autophagic flux through TFEB-mediated lysosomal dysfunction. These findings suggest that OR2T6 may be a potential therapeutic target for GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.